Regulatory approvals of pediatric oncology drugs: Previous experience and new initiatives

Journal of Clinical Oncology

Volumn 21, Issue 6, 2003, Pages 1066-1073

  Hirschfeld, Steven ^a   Ho, Peter T C ^a   Smith, Malcolm ^a   Pazdur, Richard ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACTINOMYCIN; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LOMUSTINE; MERCAPTOPURINE; METHOTREXATE; PROCARBAZINE; RETINOIC ACID; TENIPOSIDE; TIOGUANINE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT; AZACITIDINE; VINDESINE;

CHILDHOOD CANCER; DRUG APPROVAL; EWING SARCOMA; EXPERIENTIAL LEARNING; FOOD AND DRUG ADMINISTRATION; GERM CELL TUMOR; HEPATOBLASTOMA; HUMAN; LEUKEMIA; NEUROBLASTOMA; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; CHILD; OSTEOSARCOMA; PEDIATRICS; PRESCHOOL CHILD; STANDARD; UNITED STATES;

ANTINEOPLASTIC AGENTS; AZACITIDINE; CHILD; CHILD, PRESCHOOL; DRUG APPROVAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LEUKEMIA, MYELOCYTIC, ACUTE; METHOTREXATE; NEUROBLASTOMA; OSTEOSARCOMA; PEDIATRICS; TENIPOSIDE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VINDESINE;

EID: 0037445130     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.11.138     Document Type: Review

References (26)

1. Ries LAG, Eisner MP, Kosary CL, et al (eds): SEER Cancer Statistics Review, 1973-1998. Bethesda, MD, National Cancer Institute Publications, 2001
2. Bleyer WA: Principles of cancer chemotherapy in children. Cancer Bull 44:461-469, 1992
3. Matthay KK, Seeger RC, Reynolds CP, et al: Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: A report from the Children's Cancer Group. J Clin Oncol 12:2382-2389, 1994
4. Castleberry RP, Cantor AB, Green AA, et al: Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 12:1616-1620, 1994
5. Douglass EC, Reynolds M, Finegold M, et al: Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: A Pediatric Oncology Group study. J Clin Oncol 11:96-99, 1993
6. Hawkins E, Issacs H, Cushing B, et al: Occult malignancy in neonatal sacrococcygeal teratomas. A report from a Combined Pediatric Oncology Group and Children's Cancer Group study. Am J Pediatr Hematol Oncol 15:406-409, 1993
7. Anderson J, Krivit W, Chilcote R, et al: Comparison of the therapeutic response of patients with childhood acute lymphoblastic leukemia in relapse to vindesine versus vincristine in combination with prednisone and L-asparaginase: A phase III trial. Cancer Treat Rep 65:1015-1019, 1981
8. Garay G, Milone J, Dibar E, et al: Vindesine, prednisone, and daunomycin in acute lymphoblastic leukemia in relapse. Cancer Chemother Pharmacol 10:224-226, 1983
9. Tan C, Burchenal JH, Clarkson B, et al: Clinical trial of 5-azacytidine (5-azaCR). Proceedings of the Am Assoc Cancer Res Conference, 1973 (abstract 385a)
10. Glover AB, Leyland-Jones BR, Chun HG, et al: Azacitidine: 10 years later. Cancer Treat Rep 71:737-746, 1987
11. Smith MA, Ungerleider RS, Horowitz ME, et al: Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst 83:1460-1470, ; 1991
12. Rivera G, Aur RJ, Dahl GV, et al: Combined VM-26 and cytosine arabinoside in treatment of refractory childhood lymphocytic leukemia. Cancer 45:1284-1288, 1980
13. Rivera G, Dahl GV, Bowman WP, et al: VM-26 and cytosine arabinoside combination chemotherapy for initial induction failures in childhood lymphocytic leukemia. Cancer 46:1727-1730, 1980
14. Rivera G, Dahl GV, Murphy SB, et al: VM26 therapy in children with drug-refractory lymphocytic leukemia. Cancer Chemother Pharmacol 7:169-172, 1982
15. Teniposide granted marketing approval. Clin Pharm 12:6, 1993
16. Hirschfeld S, Pazdur R: Oncology drug development: United States Food and Drug Administration perspective. Crit Rev Oncol Hematol 42:137-143, 2002
17. 21 Subpart H, Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses. 21 Code of Federal Regulations 314.510, 1992
18. CFR §57 (f)9. Specific Requirements on Content and Format of Labeling for Human Prescription Drugs-Pediatric Use, 1979
19. Federal Register: Specific Requirements on Content and Format of Labeling for Human Prescription Drugs; Proposed Revision of 'Pediatric Use' Subsection in the Labeling. Final rule, 1994, pp 64240-64250
20. Federal Register: Pediatric Patients; Regulations Requiring Manufacturers to Assess the Safety and Effectiveness of New Drugs and Biological Products; Final Rule, 1998, pp 66631-66672
21. Pediatric Studies of Drugs, The Food and Drug Modernization Act, 21 USC §355a, Public Law 105-115, 1997
22. 65 Federal Register 38564-38565, Draft Guidance for Industry: Pediatric Oncology Studies in Response to a Written Request; Availability, 2000
23. FDA Oncology Tools Web site. Available at http://www.fda.gov/cder/cancer/
24. Best Pharmaceuticals for Children Act. amended to the Federal Food, Drug and Cosmetic Act. P.L. 107-109 §1789, 2002
25. FDA Pediatric Exclusivity Statistics, FDA Office of Pediatrics, http://www.fda.gov/cder/pediatric/wrstats.htm
26. Hirschfeld S, Shapiro A, Dagher R, et al: Pediatric oncology: Regulatory initiatives. Oncologist 5:441-444, 2000